Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
47 hedge funds and large institutions have $81.2M invested in Merrimack Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 6 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
170% more capital invested
Capital invested by funds: $30M → $81.2M (+$51.1M)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
79% more call options, than puts
Call options by funds: $6.49M | Put options by funds: $3.63M
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
15% more funds holding
Funds holding: 41 → 47 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$2.94M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.06M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.76M |
| 4 |
O
OrbiMed
New York
|
+$606K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$529K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.13M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.81M |
| 3 |
2L
22NW LP
Seattle,
Washington
|
-$1.78M |
| 4 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$248K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$163K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$29.1K | -3,531 | -100% |
|
MACK Hedge Fund Activity: Q4 2022 in Review
47 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2022, worth a combined $81.2M — up 170% from $30M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new MACK positions and 6 closed out — a net gain of 6 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Western Standard LLC, adding an estimated $2.94M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $4.13M sold.
- 47 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2022, up from 41 in Q3 2022.
- Funds reported $81.2M of Merrimack Pharmaceuticals, Inc. stock for Q4 2022, up 170% quarter-over-quarter.
- 12 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2022 and 6 closed out, a net change of +6 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2022 was Western Standard LLC, an estimated $2.94M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2022 was Point72 Asset Management, an estimated $4.13M sold.
Based on aggregated 13F filings for Q4 2022.